Comments
Laurus Labs Ltd is developing a third-line HIV treatment, darunavir boosted with ritonavir (DRV/r), for children.
The development is under way based on an agreement inked in June 2021 by the Hyderabad-based company, Unitaid and the Clinton Health Access Initiative (CHAI).
“Despite being available in high-income countries for over a 15-year period, a generic, fixed-dose combination paediatric version of DRV/r is still not available,” the company said in a release.
‘HIV elite controllers’ in DRC spark hope for new treatments, cure
“Through this agreement, Unitaid and CHAI are working with the company to finally address this critical need and ensure CLHIV (Children Living with HIV/AIDS) have access to high-quality second- and third-line HIV treatment,” it added.
Total HIV cases among children touch 2.8 million: UNICEF
Understanding the “small market size” for a paediatric version of DRV/r, the initiative has provided Laurus with a financial “incentive” for a portion of its development and commercialisation costs.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.